Prospective Study
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 16, 2015; 3(4): 360-367
Published online Apr 16, 2015. doi: 10.12998/wjcc.v3.i4.360
Efficacy of different doses of sugammadex after continuous infusion of rocuronium
Diego Soto Mesa, Mounir Fayad Fayad, Laura Pérez Arviza, Verónica Del Valle Ruiz, Fernando Cosío Carreño, Luis Arguelles Tamargo, Manuel Amorín Díaz, Sergio Fernández-Pello Montes
Diego Soto Mesa, Mounir Fayad Fayad, Laura Pérez Arviza, Verónica Del Valle Ruiz, Fernando Cosío Carreño, Luis Arguelles Tamargo, Department of Anaesthesiology, Hospital of Cabueñes, 33394 Gijón, Spain
Manuel Amorín Díaz, Department of Neurology, Hospital of Jove, Eduardo Castro s/n, 33290 Gijón, Spain
Sergio Fernández-Pello Montes, Department of Urology, Hospital of Cabueñes, 33394 Gijón, Spain
Author contributions: All authors contributed equally to this work; all authors designed the study, performed the research and contributed new reagents/analytic tools; Fayad Fayad M and Amorín Díaz M analyzed the data; Soto Mesa D and Amorín Díaz M wrote the paper; and all authors revised the manuscript for final submission.
Ethics approval: The study was reviewed and approved by the “ComitéÉtico de Investigación Clínica Regional del Principado de Asturias”.
Informed consent: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest: The authors declare that they have no personal conflict of interest. The translation of the manuscript has been supported by Merck Sharp and Dohme (MSD) Spain.
Data sharing: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Diego Soto Mesa, MD, Department of Anaesthesiology, Hospital of Cabueñes, C/Los Prados 395, 33394 Gijón, Spain. diegosotomesa@yahoo.es
Telephone: +34-62-0594074
Received: October 30, 2014
Peer-review started: October 30, 2014
First decision: December 26, 2014
Revised: January 28, 2015
Accepted: February 10, 2015
Article in press: February 12, 2015
Published online: April 16, 2015
Processing time: 165 Days and 9.5 Hours
Abstract

AIM: To evaluate the effects of two different doses of sugammadex after maintenance anesthesia with sevofluorane and remifentanil and deep rocuronium-induced neuromuscular blockade (NMB).

METHODS: Patients between 20 and 65 years of age, with American Society of Anesthesiologists physical status classification I-II, undergoing gynecological surgery were included in a prospective, comparative and randomized study. NMB was induced with an injection of 0.6 mg/kg of rocuronium followed by continuous infusion of 0.3-0.6 mg/kg per hour to maintain a deep block. Anesthesia was maintained with sevofluorane and remifentanil. Finally, when surgery was finished, a bolus of 2 mg/kg (group A) or 4 mg/kg (group B) of sugammadex was applied when the NMB first response in the train-of-four was reached. The primary clinical endpoint was time to recovery to a train-of-four ratio of 0.9. Other variables recorded were the time until recovery of train-of-four ratio of 0.7, 0.8, hemodynamic variables (arterial blood pressure and heart rate at baseline, starting sugammadex, and minutes 2, 5 and 10) and adverse events were presented after one hour in the post-anesthesia care unit.

RESULTS: Thirty-two patients were included in the study: 16 patients in group A and 16 patients in group B. Only 14 patients each group were recorded because arterial pressure values were lost in two patients from each group in minute 10. The two groups were comparable. Median recovery time from starting of sugammadex administration to a train-of-four ratio of 0.9 in group A and B was 129 and 110 s, respectively. The estimated difference in recovery time between groups was 24 s (95%CI: 0 to 45 s, Hodges-Lehmann estimator), entirely within the predefined equivalence interval. Times to recovery to train-of-four ratios of 0.8 (group A: 101 s; group B: 82.5 s) and 0.7 (group A: 90 s; group B: 65 s) from start of sugammadex administration were not equivalent between groups. There was not a significant variation in the arterial pressure and heart rate values between the two groups and none of the patients showed any clinical evidence of residual or recurrent NMB.

CONCLUSION: A dose of 2 mg/kg of sugammadex after continuous rocuronium infusion is enough to reverse the NMB when first response in the Train-Of-Four is reached.

Keywords: Rocuronium; Sugammadex; Neuromuscular block antagonism; Monitoring neuromuscular function; Neuromuscular block rocuronium

Core tip: The release of sugammadex in recent times has been a global shift in the strategy of the reversal of neuromuscular blockade (NMB) induced by aminosteroid neuromuscular blocking. The use of this drug has been increasing slowly, and consequently, we receive more and more questions in regards to its efficacy and safety. In this study we compared the dose of 2 mg/kg to 4 mg/kg sugammadex to reverse the NMB when first response in the train-of-four is reached after continuous infusion of rocuronium. Both doses have been shown to be effective for recovery from NMB.